Annual Meeting • November 9 – 11


Program Purpose

The Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy.

The Annual Meeting (View Schedule Online or Download a PDF) consisted of cutting-edge research presentations by experts in the field, both oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as important society projects.

Following SITC’s tradition of collaborating to advance the field, the 33rd Annual Meeting featured sessions collaboratively-developed with reputable organizations whose missions complement and align with that of SITC’s. The meeting concluded with the Hot Topic Symposium, an in-depth look at an emerging topic in the field.

Intended Audience

The audience included U.S. and international researchers, regulators and healthcare professionals involved in cancer research and clinical care. This included, but was not limited to basic, translational and clinical researchers; postdoctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals.

33rd Annual Meeting Organizers

  • Crystal L. Mackall, MD – Stanford University
  • Naiyer A. Rizvi, MD – Columbia University Medical Center
  • Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
  • Dario A.A. Vignali, PhD – University of Pittsburgh

Annual Program Committee

  • Chair: Mario Sznol, MD – Yale School of Medicine
  • Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Center
  • Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

Educational Objectives

Upon completion of this meeting, participants are able to:

  • Summarize and integrate the most recent advances in tumor immunology and cancer immunotherapy into basic, clinical and translational research
  • Analyze cutting-edge clinical trials to incorporate new research and techniques into clinical applications for cancer immunotherapy
  • Describe immune regulatory pathways that restrict and enhance immunity to tumor antigens, and identify respective targets for therapeutic intervention

The 33rd Annual Meeting was supported in part by grants from 7 Hills Pharma, AbbVie, Amgen Inc., Astellas and Seattle Genetics, AstraZeneca Pharmaceuticals LP, Bavarian Nordic A/S, Bayer HealthCare Pharmaceuticals Inc., Bristol-Myers Squibb, Celgene Corporation, Fluidigm, Genentech, Gilead Sciences, HalioDx, Incyte Corporation, Janssen Research & Development, LLC, Lilly Oncology, Merck & Co., Inc., NanoString Technologies, Novartis Oncology, Novartis Pharmaceuticals Corporation, The Parker Institute for Cancer Immunotherapy, Pfizer, Inc., Regeneron Pharmaceuticals, TESARO, Inc., Prometheus Laboratories Inc. and Replimune.

Schedule At-a-Glance